General Clinical Chemistry Analyzers and Accessories
YSI 3P LifeScience SUCROSE MEMBRANE 4/PK
Sucrose Membranes. Used to measure sucrose on YSI 2700, 2900 Series and 7100 analyzers.
RJM SALES INC MEMBRANES XYLOSE YSI 4/PK
5083394 MEMBRANES XYLOSE YSI 4/PK
Abcam Furamidine dihydrochloride, 5MG
MW 304.3 Da, Purity >=98%. A potent, selective and cell-permeable protein arginine methyltransferase 1 (PRMT1) inhibitor (IC₅₀ = 9.4 μM). Displays selectivity over PRMT5, PRMT6 and CARM1 (IC₅₀ values are 166, 283 and >400 μM respectively). Inhibits cell proliferation in leukemia cell lines.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Sunitinib, Free base, 1G
MW 398.5 Da, Purity >=99%. Sunitinib is a free base form of Sunitinib malate. A CSF-1 receptor kinase inhibitor .
The product is subject to the following: Abcam Restricted Use Statement
AdipoGen 3-oxo-C8-DL-HSL
Chemical. CAS 106983-27-1. Formula C12H19NO4. MW 241.3. Synthetic. N-3-Oxooctanoyl-DL-homoserine lactone is a small diffusible signaling molecule and is a member of N-acyl-homoserine lactone family. N-acylhomoserine lactones AHL are involved in quorum sensing, controlling gene expression, and cellular metabolism. The diverse applications of this kind of molecule include regulation of virulence in general, infection prevention, and formation of biofilms. This compound stimulates the tra gene expression. It is an autoinducer and potent antagonist.
Anton Paar Dispersion unit with integrated ultrasonication for liquid measurements in water to disperse particles in liquid medium (up to 2500 µm).
LIQUID FLOW DISPERSION UNITDispersion unit with integrated ultrasonication for liquid measurements inwater to disperse particles in liquid medium (up to 2500 µm).Flexible tank filling volume: 150-600 mL.Automated filling, rinsing, and draining.Minimum requirements to run:- outflow of the liquid (wastewater disposal connection or a tank)Recommended requirements to run:- water supply 0.1 - 3 bar
Abcam V x -745, p38 alpha MAPK inhibitor, 1MG
MW 436.3 Da. Potent, selective p38 alpha MAPK inhibitor (IC₅₀ = 10 nM), with 20-fold selectivity over p38 beta and 1000-fold selectivity over closely related kinases, ERK1 and JNK1-3.
The product is subject to the following: Abcam Restricted Use Statement
Abcam AZD-5069, 5MG
MW 476.5 Da, Purity >=98%. A potent and reversible CXCR2 chemokine receptor antagonist with potential anti-inflammatory and antineoplastic activities. Upon administration, CXC chemokine receptor 2 antagonist AZD5069 directly binds to CXCR2 and inhibits its activation. This inhibits CXCR2-mediated signaling and may inhibit tumor cell proliferation in CXCR2-overexpressing tumor cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ezetimibe, cholesterol absorption inhibitor, 100MG
MW 409.4 Da, Purity >98%. Potent selective cholesterol absorption inhibitor. Inhibits cholesterol absorption in the intestine by preventing uptake by the Niemann-Pick C1-like 1 (NPC1L1) protein, a cholesterol transporter. Ezetimibe reduces plasma cholesterol levels from 964 to 374 mg/dL, from 726 to 231 mg/dL, and from 516 to 178 mg/dL in the western, low-fat, and cholesterol-free diet mice, respectively.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Elvitegravir, quinolone HIV integrase inhibitor, 10MG
MW 447.9 Da, Purity >99%. Elvitegravir is an inhibitor of HIV integrase. It inhibits HIV integrase from HIV 1 IIIB (IC₅₀ = 0.7 nM), HIV 2 EHO (IC₅₀ = 2.8 nM) and HIV-2 ROD (IC₅₀ = 1.1 nM) in cell free assays. Elvitegravir blocks integration of HIV cDNA via inhibition of DNA strand transfer. Active against a range of HIV sub-types and against mulit-drug resistant clinical isolates. Potent (IC₅₀ range = 0.21 - 1.15 nM) HIV antiviral activity in various cell-based assays.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LY2874455, FGF/FGFR inhibitor, 25MG
MW 444.3 Da, Purity >98%. Potent FGF/FGFR inhibitor. Inhibits in vitro autophosphorylation of FGFR-1, FGFR-2, FGFR-3, and FGFR-4 with similar inhibition potency for all four FGFRs (IC₅₀ < 6.4 nM). Exhibits a 6- to 9-fold in vitro and in vivo selectivity on inhibition of FGF- over VEGF-mediated target signaling in mice.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LM22A-4, neurotrophic BDNF mimetic, 50MG
MW 339.34 Da, Purity >98%. Small molecule BDNF mimetic displaying neurotrophic activity. Partial agonist at TrkB, activating TrkB signaling. Displaces BDNF (IC₅₀ = 47 nM) in binding assays. Prevents neuronal degeneration with equal efficacy to that of BDNF in in vitro models of neurodegenerative disease. Causes hippocampal and striatal TrkB activation in mice and improved motor learning after traumatic brain injury in rats, after in vivo administraton. Improves respiratory function in a mouse model of Rett syndrome.
The product is subject to the following: Abcam Restricted Use Statement